Business
Xtant Medical Partners With B2i Digital to Educate Investors on Its Orthobiologics Innovation and Market Opportunity
The Partnership Will Deliver Centralized, Investor-focused Content to Help Retail and Institutional Audiences Gain Insight Into Xtant's Orthobiologics Platform and Long-term Value Proposition NEW YORK, NY - July 28, 2025 (NEWMEDIAWIRE) - B2i Digital ...
About this update from Xtant Medical Holdings, Inc.
[{"type":"text","content":"The Partnership Will Deliver Centralized, Investor-focused Content to Help Retail and Institutional Audiences Gain Insight Into Xtant's Orthobiologics Platform and Long-term Value Proposition","length":195,"tagName":"p"},{"type":"text","content":"NEW YORK, NY - July 28, 2025 (NEWMEDIAWIRE) - B2i Digital is pleased to announce that Xtant Medical Holdings (NYSE American: XTNT) has been named a B2i Digital Featured Company. Xtant is a global medical technology company that develops, manufactures, and markets a full-service portfolio of regenerative medicine products and related medical devices for orthopedic and neurosurgical specialists.","length":396,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":"B2i Digital, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":1000,"height":646,"url":"https://media.zenfs.com/en/newsmediawire_165/b3776ffb9f94418bfe747d9cd0a9013e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/9EPSTnLoRmIDULb78dLI_g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTYyMDtjZj13ZWJw/https://media.zenfs.com/en/newsmediawire_165/b3776ffb9f94418bfe747d9cd0a9013e","width":960,"height":620},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/zJUCh0pBpgNaYPkM7ik9pg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwMDA7aD0xMjkyO2NmPXdlYnA-/https://media.zenfs.com/en/newsmediawire_165/b3776ffb9f94418bfe747d9cd0a9013e","width":1000,"height":646}}},{"type":"text","content":"The company's vertically integrated model allows it to offer a full-service product line that includes bone-healing grafts, growth-factor biologics, cellular allografts, synthetics, and amnion products. This integration, combined with a robust R&D pipeline that includes multiple next-generation biologics scheduled for launch through 2025, underpins its strategy for driving margin improvement and long-term, sustainable growth.","length":437,"tagName":"p"},{"type":"text","content":""We are pleased to showcase Xtant Medical to our investor community at this pivotal time in the company's expansion and evolution," said David Shapiro, CEO of B2i Digital. "With its vertically integrated platform covering all five major orthobiologic categories and a clear trajectory of revenue growth, the company presents a compelling story for investors interested in the medical technology sector. Xtant&...